NCT04233697View on ClinicalTrials.gov

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 29, 2020

Primary Completion Date

July 30, 2022

Study Completion Date

July 30, 2023

Conditions
Lymphoma, T-Cell
Interventions
DRUG

Copanlisib

Novel, pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with potent activity against both the δ and α isoforms9. Copanlisib has been evaluated for the treatment of a wide variety of malignancies, including lymphoma, either as a single agent or in combination with other investigational agents.

DRUG

Romidepsin

Indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Columbia University

OTHER

NCT04233697 - Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma | Biotech Hunter | Biotech Hunter